V
Vyera Pharmaceuticals
Vyera Pharmaceuticals agreed to pay up to $28 million to third-party payors who reimbursed Daraprim between 2015 and 2022.
ClosedUnited States-wideClaim status: Closed on June 1, 2022Payout: VariesNo longer claimable
About this settlement
Settlement for third-party payors who reimbursed Daraprim, addressing alleged anti-competitive practices and price inflation.
This class action settlement resolves claims that Vyera Pharmaceuticals suppressed generic alternatives and raised prices for the malaria drug Daraprim. Eligible third-party payors who reimbursed Daraprim between 2015 and 2022 may receive compensation based on submitted documentation.
Who qualifies
- Third-party payors who paid or reimbursed Daraprim between August 7, 2015 and January 28, 2022.
- Includes health insurance companies, benefit plans, self-insured employers, and similar entities.
Varies
Claim status: Closed on June 1, 2022